The Challenge of Bleeding in Antiphospholipid Antibody-Positive Patients

Current Rheumatology Reports

Volumn 17, Issue 2, 2015, Pages

  Pazzola, Giulia ^a   Zuily, Stéphane ^b   Erkan, Doruk ^c  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adrenal hemorrhage; Anticoagulant; Antiphospholipid antibodies; Antiphospholipid syndrome; Bleeding; Catastrophic antiphospholipid syndrome; Diffuse alveolar hemorrhage; Hemorrhage; Lupus anticoagulant hypoprothombinemia syndrome; Surgery; Thrombocytopenia

Indexed keywords

CORTICOSTEROID; HYDROCORTISONE; IMMUNOGLOBULIN; PHOSPHOLIPID ANTIBODY; RITUXIMAB;

ADRENAL HEMORRHAGE; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; BLEEDING; BRONCHOSCOPY; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSE ALVEOLAR HEMORRHAGE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LUNG BIOPSY; LUNG HEMORRHAGE; LUPUS ANTICOAGULANT HYPOPROTHROMBINEMIA SYNDROME; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; REVIEW; SYNDROME; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; ADRENAL GLAND DISEASES; COMPLICATION; HEMORRHAGE; HYPOPROTHROMBINEMIAS; LUNG ALVEOLUS; LUNG DISEASES;

ADRENAL GLAND DISEASES; ANTIPHOSPHOLIPID SYNDROME; HEMORRHAGE; HUMANS; HYPOPROTHROMBINEMIAS; LUNG DISEASES; PULMONARY ALVEOLI;

EID: 84921453031     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-014-0481-0     Document Type: Review

References (95)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.
2. Cervera R, Rodríguez-Pintó I, Colafrancesco S, Conti F, Valesini G, Rosário C, et al. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Autoimmun Rev. 2014;13:699–707. This task force report provides up-to-date data regarding international CAPS registry.
3. Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2014 Jan 24. [Epub ahead of print].
4. Hunt BJ. Bleeding and coagulopathies in critical care. N Engl J Med. 2014;370:847–59.
5. Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev. 2010;10:74–9.
6. Silverberg M, Erkan D, Lockshin M. Hemorrhage in antiphospholipid syndrome: the challenge of anticoagulation. Arthritis Rheum. 2003;46:S52.
7. Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest. 2010;137:1164–71.
8. Krause ML, Cartin-Ceba R, Specks U, Peikert T. Update on diffuse alveolar hemorrhage and pulmonary vasculitis. Immunol Allergy Clin North Am. 2012;32:587–600.
9. Cartin-Ceba R, Peikert T, Ashrani A, Keogh K, Wylam ME, Ytterberg S, et al. Primary antiphospholipid syndrome-associated diffuse alveolar hemorrhage. Arthritis Care Res. 2014;66:301–10. This case series of APS-associated diffuse alveolar hemorrhage reported in the literature provides important information for patient management.
10. Deane KD, West SG. Antiphospholipid antibodies as a cause of pulmonary capillaritis and diffuse alveolar hemorrhage: a case series and literature review. Semin Arthritis Rheum. 2005;35:154–65.
11. Cervera R, Piette J-C, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27.
12. Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez-Puerta JA, Ramos-Casals M, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006;54:2568–76.
13. Scheiman Elazary A, Cohen MJ, Aamar S, Dranitzki Z, Tayer-Shifman O, Mevorach D, et al. Pulmonary hemorrhage in antiphospholipid antibody syndrome. J Rheumatol. 2012;39:1628–31.
14. Suzuki A, Asazuma N, Kikuchi E, Kawanobe T, Horimoto Y, Yokobari R, et al. “Possible primary antiphospholipid syndrome” with concurrent diffuse alveolar hemorrhaging and Libman-Sacks endocarditis mimicking catastrophic antiphospholipid syndrome. Intern Med. 2012;51:813–6.
15. Koolaee RM, Moran AM, Shahane A. Diffuse alveolar hemorrhage and Libman-Sacks endocarditis as a manifestation of possible primary antiphospholipid syndrome. J Clin Rheumatol. 2013;19:79–83.
16. Wiedermann FJ, Mayr A, Schobersberger W, Knotzer H, Sepp N, Rieger M, et al. Acute respiratory failure associated with catastrophic antiphospholipid syndrome. J Intern Med. 2000;247:723–30.
17. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368:1033–44.
18. Meroni PL, Riboldi P. Pathogenic mechanisms mediating antiphospholipid syndrome. Curr Opin Rheumatol. 2001;13:377–82.
19. Hart ML, Ceonzo KA, Shaffer LA, Takahashi K, Rother RP, Reenstra WR, et al. Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J Immunol. 2005;174:6373–80.
20. Espinosa G, Cervera R, Font J, Asherson RA. The lung in the antiphospholipid syndrome. Ann Rheum Dis. 2002;61:195–8.
21. Cervera R. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Curr Rheumatol Rep. 2010;12:70–6.
22. Strieter RM, Belperio JA, Keane MP. Host innate defenses in the lung: the role of cytokines. Curr Opin Infect Dis. 2003;16:193–8.
23. Hillerdal G, Hägg A, Licke G, Wegenius G, Scheibenpflug L. Intra-alveolar haemorrhage in the anticardiolipin antibody syndrome. Scand J Rheumatol. 1991;20:58–62.
24. West S, Arulkumaran N, Ind PW, Pusey CD. Diffuse alveolar haemorrhage in ANCA-associated vasculitis. Intern Med. 2013;52:5–13.
25. Marak CP, Joy PS, Gupta P, Bukovskaya Y, Guddati AK. Diffuse alveolar hemorrhage due to acute mitral valve regurgitation. Case Rep Pulmonol. 2013;2013:179587.
26. Dalen JE, Haffajee CI, Alpert JS, Howe JP, Ockene IS, Paraskos JA. Pulmonary embolism, pulmonary hemorrhage and pulmonary infarction. N Engl J Med. 1977;296:1431–5.
27. Vieregge GB, Harrington TJ, Andrews DM, Carpintero MF, Green DF, Nayer A. Catastrophic antiphospholipid syndrome with severe acute thrombotic microangiopathy and hemorrhagic complications. Case Rep Med. 2013;2013:915309.
28. Rangel ML, Alghamdi I, Contreras G, Harrington T, Thomas DB, Barisoni L, et al. Catastrophic antiphospholipid syndrome with concurrent thrombotic and hemorrhagic manifestations. Lupus. 2013;22:855–64.
29. Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet. 2014;383:2152–67.
30. Taffel M, Haji-Momenian S, Nikolaidis P, Miller FH. Adrenal imaging: a comprehensive review. Radiol Clin North Am. 2012;50:219–43.
31. Kovacs KA, Lam YM, Pater JL. Bilateral massive adrenal hemorrhage. Assessment of putative risk factors by the case-control method. Medicine (Baltimore). 2001;80:45–53.
32. Ramon I, Mathian A, Bachelot A, Hervier B, Haroche J, Boutin-Le Thi Huong D, et al. Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in the antiphospholipid syndrome: long-term outcome of 16 patients. J Clin Endocrinol Metab. 2013;98:3179–89. This recent paper reported initial evaluation and long-term outcome of 16 patients with bilateral adrenal hemorrhage.
33. Espinosa G, Santos E, Cervera R, Piette J-C, de la Red G, Gil V, et al. Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients. Medicine (Baltimore). 2003;82:106–18.
34. Anson BJ, Cauldwell EW. The blood supply of the kidney, suprarenal gland, and associated structures. Surg Gynecol Obstet. 1947;84:313–20.
35. Fox B. Venous infarction of the adrenal glands. J Pathol. 1976;119:65–89.
36. Arnason JA, Graziano FM. Adrenal insufficiency in the antiphospholipid antibody syndrome. Semin Arthritis Rheum. 1995;25:109–16.
37. Yap AS, Powell EE, Yelland CE, Mortimer RH, Perry-Keene DA. Lupus anticoagulant. Ann Intern Med. 1989;111:262–3.
38. Silvério RG, Caetano F, Gomes A, Sequeira M, Oliveira A. Definitive bilateral adrenal failure in antiphospholipid syndrome. Acta Reumatol Port. 2012;37:76–80.
39. Presotto F, Fornasini F, Betterle C, Federspil G, Rossato M. Acute adrenal failure as the heralding symptom of primary antiphospholipid syndrome: report of a case and review of the literature. Eur J Endocrinol. 2005;153:507–14.
40. Jordan E, Poder L, Courtier J, Sai V, Jung A, Coakley FV. Imaging of nontraumatic adrenal hemorrhage. AJR Am J Roentgenol. 2012;199:W91–8.
41. Mazodier K, Arnaud L, Mathian A, Costedoat-Chalumeau N, Haroche J, Frances C, et al. Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature. Medicine (Baltimore). 2012;91:251–60. This recent case series described features of LA-HPS patients together with an up-to-date and comprehensive review of the literature.
42. Vinet E, Rich E, Senécal J-L. Thromboembolism complicating the treatment of lupus anticoagulant hypoprothrombinemia syndrome. J Rheumatol. 2006;33:2088–90.
43. Baca V, Montiel G, Meillón L, Pizzuto J, Catalán T, Juan-Shum L, et al. Diagnosis of lupus anticoagulant in the lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature. Am J Hematol. 2002;71:200–7.
44. Harrison RL, Alperin JB, Kumar D. Concurrent lupus anticoagulants and prothrombin deficiency due to phenytoin use. Arch Pathol Lab Med. 1987;111:719–22.
45. Clauser S, Fischer A-M, Darnige L. Quinidine-induced lupus anticoagulant, hypoprothrombinemia, and antiprothrombin antibodies. Am J Hematol. 2007;82:330.
46. Erkan D, Bateman H, Lockshin MD. Lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of 2 cases and review of literature. Lupus. 1999;8:560–4.
47. Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood. 1983;61:684–92.
48. Edson JR, Vogt JM, Hasegawa DK. Abnormal prothrombin crossed-immunoelectrophoresis in patients with lupus inhibitors. Blood. 1984;64:807–16.
49. Fleck RA, Rapaport SI, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood. 1988;72:512–9.
50. Simel DL, St Clair EW, Adams J, Greenberg CS. Correction of hypoprothrombinemia by immunosuppressive treatment of the lupus anticoagulant-hypoprothrombinemia syndrome. Am J Med. 1987;83:563–6.
51. Taddio A, Brescia AC, Lepore L, Rose’ CD. Steady improvement of prothrombin levels after cyclophosphamide therapy in pediatric lupus anticoagulant hypoprothrombinemia syndrome (LAHPS). Clin Rheumatol. 2007;26:2167–9.
52. Eberhard A, Sparling C, Sudbury S, Ford P, Laxer R, Silverman E. Hypoprothrombinemia in childhood systemic lupus erythematosus. Semin Arthritis Rheum. 1994;24:12–8.
53. Raflores MB, Kaplan RB, Spero JA. Pre-operative management of a patient with hypoprothrombinemia-lupus anticoagulant syndrome. Thromb Haemost. 2007;98:248–50.
54. Saunders KH, Erkan D, Lockshin MD. Perioperative management of antiphospholipid antibody-positive patients. Curr Rheumatol Rep. 2014;16:426.
55. Cheng CK-W, Chan J, Cembrowski GS, van Assendelft OW. Complete blood count reference interval diagrams derived from NHANES III: stratification by age, sex, and race. Lab Hematol. 2004;10:42–53.
56. Stasi R, Amadori S, Osborn J, Newland AC, Provan D. Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia. PLoS Med. 2006;3:e24.
57. Cuadrado MJ, Mujic F, Muñoz E, Khamashta MA, Hughes GR. Thrombocytopenia in the antiphospholipid syndrome. Ann Rheum Dis. 1997;56:194–6.
58. Forastiero R. Bleeding in the antiphospholipid syndrome. Hematology. 2012;17 Suppl 1:S153–5.
59. Atsumi T, Furukawa S, Amengual O, Koike T. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus. 2005;14:499–504.
60. Cervera R, Boffa M-C, Khamashta MA, Hughes GRV. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus. 2009;18:889–93.
61. Cervera R, Rodríguez-Pintó I, Espinosa G, On behalf of the Task Force on Catastrophic Antiphospholipid Syndrome. Catastrophic antiphospholipid syndrome: task force report summary. Lupus. 2014;23:1283–5.
62. Stasi R. How to approach thrombocytopenia. Hematol Am Soc Hematol Educ Program. 2012;2012:191–7.
63. Gauer RL, Braun MM. Thrombocytopenia. Am Fam Physician. 2012;85:612–22. This comprehensive review can help physicians in ruling-out differential diagnoses of thrombocytopenia in APS patients.
64. Vázquez-Mellado J, Llorente L, Richaud-Patin Y, Alarcón-Segovia D. Exposure of anionic phospholipids upon platelet activation permits binding of beta 2 glycoprotein I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects. J Autoimmun. 1994;7:335–48.
65. Galli M, Daldossi M, Barbui T. Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies. Thromb Haemost. 1994;71:571–5.
66. Macchi L, Rispal P, Clofent-Sanchez G, Pellegrin JL, Nurden P, Leng B, et al. Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Br J Haematol. 1997;98:336–41.
67. Godeau B, Piette JC, Fromont P, Intrator L, Schaeffer A, Bierling P. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome. Br J Haematol. 1997;98:873–9.
68. Diz-Küçükkaya R, Hacihanefioğlu A, Yenerel M, Turgut M, Keskin H, Nalçaci M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. 2001;98:1760–4.
69. Yang Y-J, Yun G-W, Song I-C, Baek S-W, Lee K-S, Ryu HW, et al. Clinical implications of elevated antiphospholipid antibodies in adult patients with primary immune thrombocytopenia. Korean J Intern Med. 2011;26:449–54.
70. Comellas-Kirkerup L, Hernández-Molina G, Cabral AR. Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study. Blood. 2010;116:3058–63.
71. Gernsheimer T, James AH, Stasi R. How I treat thrombocytopenia in pregnancy. Blood. 2013;121:38–47.
72. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120:4160–7.
73. Martin-Toutain I, Piette JC, Diemert MC, Faucher C, Jobic L, Ankri A. High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia. Lupus. 2007;16:79–83.
74. Alpert D, Mandl LA, Erkan D, Yin W, Peerschke EI, Salmon JE. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome. Ann Rheum Dis. 2008;67:395–401.
75. Pauzner R, Greinacher A, Selleng K, Althaus K, Shenkman B, Seligsohn U. False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost. 2009;7:1070–4.
76. Alpert DR, Salmon JE. False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus: a rebuttal. J Thromb Haemost. 2010;8:1439–41.
77. Warkentin TE. Antiphospholipid and anti-PF4 antibodies: an association affecting anti-PF4/heparin assay analysis. J Thromb Haemost. 2009;7:1067–9.
78. Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia: eight cases with thrombotic-hemorrhagic complications. Ann Surg. 1977;186:752–8.
79. Hursting MJ, Verme-Gibboney CN. Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study. J Cardiovasc Pharmacol. 2008;52:561–6.
80. Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. 2006;108:1492–6.
81. Kim K-J, Baek I-W, Yoon C-H, Kim W-U, Cho C-S. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies. Br J Haematol. 2013;161:706–14. This recent study showed that a substantial proportion of ITP patients were aPL-positive and that lupus anticoagulant was an independent risk factors for thrombosis.
82. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190–207.
83. Erkan D, Vega J, Ramón G, Kozora E, Lockshin MD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013;65:464–71.
84. Espinosa G, Bucciarelli S, Cervera R, Lozano M, Reverter J-C, de la Red G, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis. 2004;63:730–6.
85. George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. Semin Thromb Hemost. 2013;39:153–60.
86. Cervera R. CAPS Registry. Lupus. 2012;21:755–7.
87. Trappe R, Loew A, Thuss-Patience P, Dörken B, Riess H. Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab—monitoring of antiphospholipid and anti-GP antibodies: a case report. Ann Hematol. 2006;85:134–5.
88. Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13:685–96.
89. Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57:173–80.
90. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713–9.
91. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848–53.
92. Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170:1433–41.
93. Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med. 2000;160:2042–8.
94. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e152S–84S.
95. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995–1008.